intuitively two (or more) measurements seem essential in order to investigate the change in a biomarker. This note illustrates how this simple intuition fails, leading to imprecise and biased results in common situations. We will consider the biomarker CD4 T Lymphocytes + count (CD4) in a trial or observational study of Human Immunodeficiency Virus (HIV) infection as an example. The primary objective of a trial could be to evaluate the change in CD4 after the initiation of a randomised intervention, or analysis of a change in the biomarker could be a retrospective exploratory analysis in both types of study. In either case, some participants may not have two marker measurements available, and this is likely to occur more frequently in the latter because this statistical analysis was not planned. The question is: should these participants be excluded or not? In other words, should one use a complete data set or the whole sample?
Today, most statistical packages include methods which work with different numbers of measurements for each participant, technically termed unbalanced data , . Such approaches allow all participants to be included, those with only one measurement as well " " 2 3 as those fortunate enough to have more. One such method is a linear mixed or random effects model , . The general idea is to model the 2 4
absolute levels of biomarkers from all participants -participants with only one value can still contribute population level information about the average biomarker levels at the time of their measurement. However, this kind of model does not just estimate overall levels in the study population it assesses how different individual participants are from this population average. By making the reasonable assumption -that individual level baselines (intercepts) and subsequent changes (slopes) in the participant population come from a statistical distribution (usually Normal), one can predict the slope of a patient with a single measurement only, for example, just at baseline.
How does it work intuitively?
When measurements from an individual are not available during follow-up, the method behaves as if that participant had contributed the follow-up values of patients whose baseline level and other measured characteristics are most similar.
How valid is the estimation of a slope when some patients only have one marker measurement?
In statistics, it is usual to distinguish three kinds of missing data : 1) missing completely at random (MCAR), 2) missing at 5-7 ' ' ' random (MAR) or 3) informatively missing . The first situation occurs when a marker value is missing at a given time independently of
other values of the marker or explanatory variables (measured or not). For example, it happens if the test tube is broken by accident. A missing observation is missing at random when the probability of not observing this value may depend on previously observed values.
' '
For instance, values could be missing after a participant reaches a threshold level (e.g. 200 cells/ L) that defines the end of the follow-up μ in a given study. Finally, a missing observation is informatively missing when the probability that data are missing depends on some ' ' unobserved values. This situation could happen when a participant misses a visit because they are too sick (related to very low CD4). A linear mixed or random effects model as described above will provide unbiased estimates when missing measurements are due to either of the first two mechanisms. This is not the case for the third mechanism.
What about the intuitive alternative of excluding patients with only one measurement available?
Excluding some participants without a second measurement for particular reasons is analogous to a complete case analysis , although ' ' this is more often recognised in the context of missing explanatory variables. Such complete case analysis is known to be valid when ' ' only the data are missing completely at random, meaning in our example if the fact that a patient has no follow-up measurement is not only linked to the baseline value or any explanatory variable. In this situation, excluding patients with only one measurement from analyses will produce estimates which are unbiased but with a poorer precision (higher variance, larger confidence intervals) compared to estimates from random effect models, that is, will give basically the same results but with reduced statistical power to detect genuine differences.
However, a more likely situation is that data are missing at random , that is whether or not a biomarker value is observed depends on at 
An example
We illustrate this with a simulation study based on the increase in CD4 cell count after initiation of antiretroviral treatment in HIV + infected patients . Lets take a study population of 100 patients with three measurements, i.e. at time 0 (treatment initiation), 1 and 2 years. 
Case 1: random loss to follow-up
As expected, when participants were randomly lost to follow-up, the three statistical analyses gave similar estimates of mean CD4 at baseline and during follow-up ( ). However, excluding those with only one measurement led to an increase of almost 40 in the Table 1 % standard error of the estimates compared to the analyses performed either on the complete dataset or including all patients. In the present example, this led to slightly wider confidence intervals ( ). Table 1 Case 2: loss to follow-up when baseline CD4 below 200 cells/ L μ All data points and estimated trajectories are shown in . Estimates from the complete dataset and from all available data also Figure 1 including participants with only one measurement were unbiased ( ), that is the baseline CD4 and rate of change in CD4 were both Table 1 estimated correctly compared to the underlying model used to generate the data. In contrast, estimates restricted to participants with two or more measurements were biased upward: with a difference of 60 cells/ L for the baseline value and 31 cells/year for the rate of increase.
This result is expected because we generated missing at random (but not missing completely at random ) data by deleting subsequent 
Conclusion
Of course, in this artificial example, we knew that analysis excluding participants with only one measurement was likely to overestimate the increase in CD4 because of the way we generated the data. Unfortunately, when faced with real-life data it is not +
Figure 1
Data and estimation of mean CD4 cells/ L according to data used: complete dataset (grey), excluding patients without follow-up μ measurements due to low baseline CD4 cell count (black), including all patients (red). Note: estimates from the complete dataset (in grey) are very similar to with estimates from model fitted with patients having one measurement available or more (in red) (see ). Table 1 inserm-00336900, version 1 -4 Aug 2009 
